Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:ELUT NASDAQ:MIST NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.12-2.2%$1.65$0.78▼$4.98$145M1.871.07 million shs747,764 shsELUTElutia$0.92-4.7%$1.00$0.50▼$2.50$41.09M0.8590,602 shs23,617 shsMISTMilestone Pharmaceuticals$1.07-5.3%$1.29$1.00▼$3.06$140.68M0.971.02 million shs2.57 million shsUNCYUnicycive Therapeutics$4.94-3.7%$6.53$3.71▼$8.74$140.53M1.792.31 million shs1.01 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-1.76%-12.55%+7.73%-70.54%-64.32%ELUTElutia-4.73%-3.68%-8.41%-8.50%-53.55%MISTMilestone Pharmaceuticals-5.31%-13.01%-13.71%-41.21%-30.97%UNCYUnicycive Therapeutics-3.70%-13.18%-30.72%-31.01%+4.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.12-2.2%$1.65$0.78▼$4.98$145M1.871.07 million shs747,764 shsELUTElutia$0.92-4.7%$1.00$0.50▼$2.50$41.09M0.8590,602 shs23,617 shsMISTMilestone Pharmaceuticals$1.07-5.3%$1.29$1.00▼$3.06$140.68M0.971.02 million shs2.57 million shsUNCYUnicycive Therapeutics$4.94-3.7%$6.53$3.71▼$8.74$140.53M1.792.31 million shs1.01 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-1.76%-12.55%+7.73%-70.54%-64.32%ELUTElutia-4.73%-3.68%-8.41%-8.50%-53.55%MISTMilestone Pharmaceuticals-5.31%-13.01%-13.71%-41.21%-30.97%UNCYUnicycive Therapeutics-3.70%-13.18%-30.72%-31.01%+4.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.33Hold$6.25460.54% UpsideELUTElutia 2.00Hold$6.00555.74% UpsideMISTMilestone Pharmaceuticals 2.67Moderate Buy$7.25577.57% UpsideUNCYUnicycive Therapeutics 2.43Hold$21.75340.28% UpsideCurrent Analyst Ratings BreakdownLatest ELUT, ADCT, UNCY, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)7/21/2026UNCYUnicycive Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026MISTMilestone Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/13/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/7/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)7/1/2026UNCYUnicycive Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSpeculative Buy$18.00 ➝ $13.006/30/2026UNCYUnicycive Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/30/2026UNCYUnicycive Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $15.006/17/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/9/2026UNCYUnicycive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M1.74N/AN/A($1.50) per share-0.74ELUTElutia$12.29M3.19N/AN/A$0.65 per share1.41MISTMilestone Pharmaceuticals$1.55M85.95N/AN/A$0.39 per share2.74UNCYUnicycive Therapeutics$680K198.98N/AN/A$1.41 per share3.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)ELUTElutia$53.38M$0.861.06N/AN/A312.09%N/A-53.97%8/14/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.68N/AN/AN/AN/A-339.33%-61.79%8/12/2026 (Estimated)UNCYUnicycive Therapeutics-$26.56M-$2.21N/A0.63N/AN/A-134.69%-84.51%8/13/2026 (Estimated)Latest ELUT, ADCT, UNCY, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026ELUTElutia-$0.15N/AN/AN/A$2.90 millionN/A8/13/2026Q2 2026UNCYUnicycive Therapeutics-$0.4710N/AN/AN/A$22.22 millionN/A8/12/2026Q2 2026MISTMilestone Pharmaceuticals-$0.18N/AN/AN/A$0.82 millionN/A8/11/2026Q2 2026ADCTADC Therapeutics-$0.19N/AN/AN/A$18.89 millionN/A5/14/2026Q1 2026ELUTElutia-$0.15-$0.17-$0.02-$0.17$3.00 million$3.11 million5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.06-$0.20-$0.26-$0.20$30.12 million$0.24 million5/12/2026Q1 2026UNCYUnicycive Therapeutics-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.02ELUTElutiaN/A2.051.94MISTMilestone Pharmaceuticals1.619.189.09UNCYUnicycive TherapeuticsN/A2.402.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%ELUTElutia74.03%MISTMilestone Pharmaceuticals86.18%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%ELUTElutia17.80%MISTMilestone Pharmaceuticals5.03%UNCYUnicycive Therapeutics6.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableELUTElutia18042.78 million35.17 millionNot OptionableMISTMilestone Pharmaceuticals30124.50 million118.24 millionOptionableUNCYUnicycive Therapeutics927.39 million25.74 millionNot OptionableELUT, ADCT, UNCY, and MIST HeadlinesRecent News About These CompaniesCritical Comparison: Phio Pharmaceuticals (NASDAQ:PHIO) versus Unicycive Therapeutics (NASDAQ:UNCY)July 27 at 2:44 AM | americanbankingnews.comUnicycive Therapeutics (NASDAQ:UNCY) Downgraded to Strong Sell Rating by Zacks ResearchJuly 23, 2026 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 19, 2026 | marketbeat.comUnicycive Therapeutics (UNCY) Gets a Buy from Maxim GroupJuly 16, 2026 | theglobeandmail.comUNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud InvestigationJuly 13, 2026 | globenewswire.comGuggenheim Remains a Buy on Unicycive Therapeutics (UNCY)July 10, 2026 | theglobeandmail.comUNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.July 10, 2026 | globenewswire.comUNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.July 8, 2026 | businesswire.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...July 8, 2026 | tmcnet.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmJuly 8, 2026 | businesswire.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzJuly 8, 2026 | tmcnet.comSecurities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzJuly 7, 2026 | businesswire.comUNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsJuly 6, 2026 | globenewswire.comUnicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover LossesJuly 6, 2026 | newsfilecorp.comNHC Wainwright Has Negative Outlook for UNCY Q2 EarningsJuly 3, 2026 | marketbeat.comBragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the FirmJuly 2, 2026 | globenewswire.comUnicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing DeficienciesJuly 2, 2026 | finance.yahoo.comUNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudJuly 1, 2026 | businesswire.comUNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Encouraged to Contact the FirmJuly 1, 2026 | globenewswire.comUS FDA declines to approve Unicycive's kidney disease drugJune 30, 2026 | reuters.comUNCY stock crashed 45% today – why did FDA reject its kidney disease NDA for a second time?June 30, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELUT, ADCT, UNCY, and MIST Company DescriptionsADC Therapeutics NYSE:ADCT$1.12 -0.03 (-2.19%) Closing price 07/28/2026 03:59 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 07/28/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Elutia NASDAQ:ELUT$0.92 -0.05 (-4.73%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$0.92 0.00 (0.00%) As of 07/28/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Milestone Pharmaceuticals NASDAQ:MIST$1.07 -0.06 (-5.31%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$1.07 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Unicycive Therapeutics NASDAQ:UNCY$4.94 -0.19 (-3.70%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$4.99 +0.05 (+1.09%) As of 07/28/2026 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
